Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
about
Management of HBV Infection in Liver Transplantation PatientsKASL clinical practice guidelines: management of chronic hepatitis BBenefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosisNucleoside/nucleotide analogues in the treatment of chronic hepatitis BOutcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting listThe role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice.Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individualsThe survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosisThe new liver allocation system: moving toward evidence-based transplantation policy.Hepatitis B: progress in the last 15 years.Prevention of recurrent hepatitis B post-liver transplantation.Treatment of hepatitis B in decompensated liver cirrhosis.Emerging drugs for hepatitis B.Current pharmacotherapy for the treatment of chronic hepatitis B.Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients.Review article: Nucleoside analogues for the treatment of chronic hepatitis B.Liver transplantation for viral hepatitis.Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Optimizing management strategies in special patient populations.Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analoguesLamivudine treatment in patients with chronic hepatitis B and cirrhosis.Prevention of hepatitis B virus recurrence after liver transplantation.Future prospectives for the management of chronic hepatitis B.The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion ChemotherapyAntiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis.Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation.Hepatitis B therapy.Treatment of special populations with chronic hepatitis B infection.Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?Reversibility of hepatitis B virus cirrhosis after therapy: who and why?Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin.Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.Prevention of hepatitis B virus-associated liver diseases by antiviral therapy.Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
P2860
Q24529103-BE65ED83-3104-4C7C-A968-E1718D58A2FDQ26752475-43ACD4BC-2603-404A-B3F7-5456F434F851Q26783356-84C46464-BFB6-4293-9C69-BE020EDD98A1Q27030828-B14F83AB-9B50-41F8-8405-0667CEEC46D2Q30440211-6AF1FED3-4C2E-46B9-9B63-A9998E2705C9Q33345288-F953089A-6F27-4A43-B233-24782D444EFFQ34052838-62323CA8-DFF5-4E96-BE73-337B34FFDB1BQ34510569-A4BF92AF-1B99-46A6-B345-39EDC5C5BBD8Q34802534-22740E35-4960-46D8-AC0F-A64DF3850791Q34936238-5623C79D-AAEC-4716-A8BA-4D8F57374097Q34936261-B869469D-8A9A-40ED-964B-3AC8C595242FQ35207784-DE67EB89-3645-410A-B8DE-8D2FA89E78D7Q35359369-78462767-3140-4BC6-A7F1-BBD07DFE3CD6Q35548194-25E87558-7088-4FB5-9E35-08FD6B3D1DBDQ35825117-32FF1365-5614-4B0E-804A-C55DDD992DF2Q35987869-01001B71-C7C2-4919-8977-BBE7BB072BB9Q36027124-2EA20AB7-4F08-4E46-AF27-67EDADB3E2BBQ36028324-2859F20E-AC29-4B10-AF7B-8F4B8F4E07F6Q36153966-BA87FC03-941A-4382-9856-EACDE7EFD2E8Q36382644-E226DBC8-5AD5-463E-98F0-C912906F8C37Q36442537-F2DC3749-E36B-41AE-B70C-C40B989AE714Q36573919-639B56D1-A428-4297-8F5A-D511BE21EBB6Q36652077-0ADFD5D8-727D-4C55-AC54-70E1963EF754Q36841719-7146C0A2-1D3B-4587-91B1-DC40D2EF52A0Q37204018-153050C4-4788-4D5A-9C97-646A863C7EF4Q37266410-04B5C387-48A3-40BC-B1DC-FE2875728A46Q37278194-55DBA5B6-EC7C-4F24-BD72-79AEEF2EED82Q37425703-357B5C1F-C25C-4694-8BDB-65906D8E04D2Q37495757-39CA8D33-E52A-4216-8D63-36D307EEA4C8Q37855531-46F0BA5D-D245-4969-A517-855C8FF903D8Q37886158-8F022112-EF85-461D-85D4-D954EC7E1090Q38174255-9B7DA326-B97C-4D8B-99A1-7482E8189001Q38295837-17003587-92FE-44D3-8454-ED6FEEBC6C27Q38514411-14051446-D4E7-410F-84AB-1ECC7CF88D1AQ38655765-F5BB0E09-91F2-450B-8814-C8D7DB303ED0Q38793117-BD8E0974-691E-43E3-85BB-6933015BCB1DQ40141719-C80AB8D2-011C-44D8-B6AC-80EC32A28472Q40629471-0F0745EA-30AA-4604-B238-AF84C9DB9A92Q40637196-7DEA237E-F3D4-4F36-B147-EC94B230BA3FQ40659586-9E0673F1-C88A-4283-B8CD-FD2A4948CE06
P2860
Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Lamivudine treatment is benefi ...... g a matched, untreated cohort.
@en
Lamivudine treatment is benefi ...... g a matched, untreated cohort.
@nl
type
label
Lamivudine treatment is benefi ...... g a matched, untreated cohort.
@en
Lamivudine treatment is benefi ...... g a matched, untreated cohort.
@nl
prefLabel
Lamivudine treatment is benefi ...... g a matched, untreated cohort.
@en
Lamivudine treatment is benefi ...... g a matched, untreated cohort.
@nl
P2093
P356
P1433
P1476
Lamivudine treatment is benefi ...... g a matched, untreated cohort.
@en
P2093
P304
P356
10.1053/JHEP.2001.26512
P407
P577
2001-08-01T00:00:00Z